- The first trial in Rhode Island state court against Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) alleged responsibility for the opioid crisis begins jury selection Monday.
- The case begins over whether Teva contributed to an opioid crisis that has caused more than 500,000 deaths over the past two decades.
- Rhode Island says Teva created a "public nuisance" by downplaying the risks of opioid addiction and promoting the off-label use of fentanyl-based opioids that were approved only for certain types of cancer pain.
- According to a Teva court filing, Rhode Island is seeking $5.9 billion from the companies.
- Also See: Teva, Texas Enter $225M Opioid Settlement Agreement.
- Teva subsidiaries Actavis Pharma and Cephalon Inc are also defendants in Rhode Island Superior Court in Providence.
- The companies have denied the allegations, saying they sold legal and approved drugs for pain treatment.
- In court filings by Teva, it calls Rhode Island's lawsuit an improper attempt to blame a wide-ranging public health crisis on "a small subset of opioid manufacturers" that make "niche" medicines like Actiq and Fentora.
- Teva also sells generic opioids such as oxycodone.
- Price Action: TEVA shares are down 2.61% at $7.29 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Rhode Island's Opioid Trial Against Teva Begins Today: Reuters
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks